Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2013 (2013), Article ID 368731, 5 pages
http://dx.doi.org/10.1155/2013/368731
Research Article

Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing

Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark

Received 3 September 2013; Revised 12 November 2013; Accepted 12 November 2013

Academic Editor: Bent Ejlertsen

Copyright © 2013 Tim S. Poulsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. C. Wolff, M. E. H. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 1, pp. 18–43, 2007. View at Google Scholar · View at Scopus
  2. D. Mayr, S. Heim, K. Weyrauch et al., “Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization,” Histopathology, vol. 55, no. 6, pp. 716–723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. K. V. Nielsen, S. Müller, T. S. Poulsen, S. Gabs, and A. Schonau, “Chapter 11: combined use of PNA and DNA for fluorescence in situ hybridization (FISH),” in Peptide Nucleic Acids: Protocols and Applications, P. E. Nielsen and M. Egholm, Eds., pp. 227–260, Horizon Bioscience, Norfolk, UK, 2nd edition, 2004. View at Google Scholar
  4. C. M. Hansen, “Chapter 14: applications–environmental stress cracking in polymers,” in Hansen Solubility Parameters: A User's Handbook, pp. 269–292, Taylor & Francis, 2nd edition, 2007. View at Google Scholar
  5. G. Pauletti, W. Godolphin, M. F. Press, and D. J. Slamon, “Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization,” Oncogene, vol. 13, no. 1, pp. 63–72, 1996. View at Google Scholar · View at Scopus
  6. M. Tanner, D. Gancberg, B. A. D. Leo et al., “Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples,” The American Journal of Pathology, vol. 157, no. 5, pp. 1467–1472, 2000. View at Google Scholar · View at Scopus
  7. H. H. Rossing, M.-L. M. Talman, A.-V. Lænkholm, and V. T. Wielenga, “Implementation of TMA and digitalization in routine diagnostics of breast pathology,” APMIS, vol. 120, no. 4, pp. 341–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. J. A. Dekker, S. T. Borg, G. K. J. Hooijer et al., “Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach,” vol. 120, pp. 341–347, 2012. View at Google Scholar
  9. K. Park, J. Kim, S. Lim, S. Han, and J. Y. Lee, “Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray,” Modern Pathology, vol. 16, no. 9, pp. 937–943, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. D. Francis, M. A. Jones, G. F. Beadle, and S. R. Stein, “Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome,” Diagnostic Molecular Pathology, vol. 18, no. 2, pp. 88–95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. D. Graham, D. Faratian, F. Rae, and J. S. J. Thomas, “Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization,” Histopathology, vol. 52, no. 7, pp. 847–855, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. K. E. Olsen, H. Knudsen, B. B. Rasmussen et al., “Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes,” Acta Oncologica, vol. 43, no. 1, pp. 35–42, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Gong, W. Sweet, Y.-J. Duh et al., “Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer a multicenter study using conventional scoring criteria and the new asco/cap recommendations,” American Journal of Clinical Pathology, vol. 131, no. 4, pp. 490–497, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. R. Landis and G. G. Koch, “The measurement of observer agreement for categorical data,” Biometrics, vol. 33, no. 1, pp. 159–174, 1977. View at Google Scholar · View at Scopus
  15. D. Mayr, S. Heim, K. Weyrauch et al., “Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization,” Histopathology, vol. 55, no. 6, pp. 716–723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. García-Caballero, D. Grabau, A. R. Green et al., “Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European Multicentre Study involving 168 specimens,” Histopathology, vol. 56, no. 4, pp. 472–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Gupta, L. P. Middleton, M. J. Whitaker, and J. Abrams, “Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer,” American Journal of Clinical Pathology, vol. 119, no. 3, pp. 381–387, 2003. View at Google Scholar · View at Scopus
  18. J. Jacquemier, F. Spyratos, B. Esterni et al., “SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases,” BMC Cancer, vol. 13, pp. 351–361, 2013. View at Publisher · View at Google Scholar
  19. H. Seol, H. J. Lee, Y. Choi et al., “Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance,” Modern Pathology, vol. 25, pp. 938–948, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Starczynski, N. Atkey, Y. Connelly et al., “HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations,” American Journal of Clinical Pathology, vol. 137, no. 4, pp. 595–605, 2012. View at Publisher · View at Google Scholar · View at Scopus